Japanese drug maker Astellas Pharma’s drug for invasive fungal infection has received positive signal from a U.S. FDA panel of experts. The FDA panel voted in favor of isavuconazonium to treat invasive aspergillosis. The rare and life-threatening fungal infection invasive aspergillosis usually attacks patients with weak immune system.
After carefully reviewing the safety and the positive impact of the drug during the trials, FDA panel has voted 11-0 in favor of the approval for the drug. The final approval decision is expected by March 8. After a strong support from the FDA panel, the drug might get FDA nod.